c 10

Norchlorcyclizine (C-10) is a partially selective NPR-B inhibitor. It also is an inhibitor of human tyrosyl-DNA phosphodiesterase 1.

UNC1062 is a highly selective tyrosine kinase inhibitor that specifically targets MERTK. This compound effectively suppresses MERTK-mediated downstream signaling, induces apoptosis in cell cultures, reduces colony formation in soft agar, and inhibits invasion of melanoma cells. Notably, UNC1062 demonstrates potent inhibition of MERTK kinase activity, with an IC50 of 1.1 nM and a Morrison Ki of 0.33 nM. It also displays specificity within the TAM family, exhibiting IC50 values of 60 nM for TYRO3 and 85 nM for AXL [1].

C 101248 (KCNK13-IN-1) is a selective and potent tandem pore halogen inhibitor of K+ channel 1 (THIK-1) inhibitor and human and mouse KCNK13 inhibitor.C 101248 inhibits IL-1β release in a concentration-dependent manner and can be used for the study of inflammation induced by neurodegenerative disorders.

c-Fms-IN-10, a derivative of thieno [3,2-d] pyrimidine, is a kinase inhibitor of FMS (Colony-stimulating factor-1 receptor, CSF-1R; IC50: 2 nM) with anti-tumor activity.

C-Myc Inhibitor 10 (compound 17), exhibiting enhanced cellular potency, benefits from increased permeability due to the methylation of the morpholine nitrogen [1].

7-Xylosyl-10-deacetyltaxol C is a natural product from Taxus wallichiana Zucc.

C-HEGA-10 is a useful organic compound for research related to life sciences. The catalog number is TF0012 and the CAS number is 864434-15-1.

c-Met-IN-10 is a potent c-Met kinase inhibitor (IC50: 16 nM). c-Met-IN-10 inhibits the activity of cancer cells A549, H460 and HT-29, and inhibits A549 cell movement by inhibiting HT-29 cell colony formation, which in turn induces apoptosis in HT-29 and A549 cells. c-Met-IN-10 can be used in anticancer studies. -Met-IN-10 is capable of being used in anticancer studies.

NSC 109555 is a selective, reversible, ATP-competitive Chk2 inhibitor (IC50 = 0.2 μM) that displays no effect on a range of other kinases including Chk1 (IC50 > 10 μM). Inhibits histone H1 phosphorylation (IC50 = 0.24 μM) and attenuates mitochondrial ATP synthesis. Exhibits antiproliferative activity in a number of leukemias in vivo.

AR-C 102222 is an iNOS inhibitor.

AntibioticDC 102 is a novel glycosylated pyrrole (1,4) benzodiazepine-class antibiotic targeting Bacillus subtilis, with a minimum inhibitory concentration (MIC) of 42 μg mL. The lethal dose 50 (LD50) in mice, when administered intraperitoneally (i.p), is 1.5 mg mL.

Somatostatin RC 102 is a peptide hormone. It regulates the endocrine system and affects neurotransmission and cell proliferation via interaction with G protein-coupled somatostatin receptors and inhibition of the release of numerous secondary hormones.

RAC 109 is a chiral antiarrhythmic agent.

MC 1046 is an impurity of Calcipotriol. Calcipotriol is a ligand of VDR-like receptors.

Chk2 inhibitor,ATP-competitive

LL-C 10037alpha is a gamma-aminoepoxysemiquinone isolated from Streptomyces.

NSC 105204 is a bioactive chemical.

CC 1014 is a polypeptide antibiotic isolated from Penicillium lilacinum that inhibits phosphorylation of ADP, Mg ATPase.

NSC 107512 is a class of sangivamycin-like molecules (SLM). NSC 107512 is a potent cyclin-dependent kinase 9(CDK9) inhibitor that inhibits multiple myeloma tumors growth and induces apoptosis [1].

GC 10284 is an agent of pesticide.

JNK-IN-8 (JNK Inhibitor XVI) is an irreversible JNK1 2 4 inhibitor (IC50: 4.7 18.7 1 nM) with over 10-fold selectivity compared to MNK2 and Fms, and no inhibition of Met, c-Kit, or PDGFRβ in the A375 cell line.

GP-82996 (CINK4) is a pharmacological inhibitor specifically targeting CDK4 6, exhibiting IC50 values of 1.5 μM for CDK4 cyclin D1, 5.6 μM for CDK6 cyclin D1, and 25 μM for Cdk5 p35. It effectively induces apoptosis in U2OS cancer cells, positioning it as a potential investigational tool in cancer research [1] [2].

Chlamydia pneumoniae-IN-1 (compound 55), a benzimidazole derivative, exhibits potent antibacterial activity, inhibiting 99% of C. pneumoniae growth at a concentration of 10 μM while maintaining 95% viability of host cells. It effectively inhibits the CV-6 strain of C. pneumoniae with a minimum inhibitory concentration (MIC) of 12.6 μM, demonstrating its antichlamydial efficacy [1].

Pexidartinib (PLX-3397) is a capsule containing a small-molecule receptor tyrosine kinase (RTK) inhibitor targeting KIT, CSF1R, and FLT3, with potential antineoplastic activity.